SYNDESI THERAPEUTICS

Active

Public limited companyfounded 2017active for 8 yearsAvenue Einstein 14, 1300 Wavre, BelgiumKBO/BCE: BE 0686.599.355

Summary

The computed 12-month bankruptcy probability of SYNDESI THERAPEUTICS is 1.9% (moderate). The 2025 annual accounts show negative equity (-€129.9m) and a net result of -€12.0m. The figures fluctuate too strongly year-on-year for a reliable trend projection. Its solvency ranks better than 5% of 239 sector peers (NACE 72, financial year 2025). The company has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals.

Risk analysisFollow Report Compare

SYNDESI THERAPEUTICSActiveChecked score 52/100

Risk analysis Report Compare

Activity

Research and development on biotechnology

NACE 72101

1 site

Size

€607,532total assets 2025

Equity: -€129.9m
Loss: -€12.0m

Financial health

52 Fair Checked score 2025

Bankruptcy probabilitywithin 12 months: 1.9%

Structure

Parent: AbbVie Inc.

Erica SilbigerDirector

Auditor: EY Réviseurs d'Entreprises SRL2025 accounts 53 days early6 of 23 deeds summarised

Why 52raises riskLiquidity: current ratio 0.01Negative equity -€129.9mLoss of €12.0m, the second in a row (financial year 2025)lowers riskSize: total assets €607,532Show the evidence

Checked score

Score 2025

52 / 100

Fair

Probability in this band: 1.5% to 4.2%

Financially better than 13% of its sector peers (NACE 72, micro)

Every signal that counts is listed under Signals.

Financial strength · tick = 2024

Weak

Solvency 0=

equity -21385.2% of total assets

Liquidity 0=

short-term debt 19158.3%

Profitability 0=

return on assets -1968.1%

Bankruptcy probability, 12 months

1.9% Moderate

0%0.5%1.5%4%10%≥ 25%

About 2 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (935 companies, NACE 72, micro)

Last 24 months 11-2024: 3.9% 12-2024: 3.9%● unchanged vs 11-2024 01-2025: 3.9%● unchanged vs 12-2024 02-2025: 3.9%● unchanged vs 01-2025 03-2025: 3.8%▼ -0.1 percentage points vs 02-2025 04-2025: 3.7%▼ -0.1 percentage points vs 03-2025 05-2025: 3.6%▼ -0.1 percentage points vs 04-2025 06-2025: 3.5%▼ -0.1 percentage points vs 05-2025 07-2025: 3.9%▲ +0.4 percentage points vs 06-2025 08-2025: 3.9%● unchanged vs 07-2025 09-2025: 4.0%▲ +0.1 percentage points vs 08-2025highest value 10-2025: 4.0%● unchanged vs 09-2025highest value 11-2025: 4.0%● unchanged vs 10-2025highest value 12-2025: 4.0%● unchanged vs 11-2025highest value 01-2026: 2.6%▼ -1.4 percentage points vs 12-2025 02-2026: 2.6%● unchanged vs 01-2026 03-2026: 2.6%● unchanged vs 02-2026 04-2026: 2.5%▼ -0.1 percentage points vs 03-2026 05-2026: 2.5%● unchanged vs 04-2026 06-2026: 2.5%● unchanged vs 05-2026 07-2026: 1.9%▼ -0.6 percentage points vs 06-2026lowest value 08-2026: 1.9%● unchanged vs 07-2026lowest value 09-2026: 1.9%● unchanged vs 08-2026lowest value 10-2026: 1.9%● unchanged vs 09-2026lowest value

No credit on open account

Liquidity insufficient (current ratio 0.01, compared with 0.01 in 2024, below 1), and equity is negative.

How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100	Excellent	under 0.55%
60-74	Healthy	0.55% to 1.5%
45-59	Fair	1.5% to 4.2%
25-44	Weak	4.2% to 15.0%
0-24	Critical	over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, micro): better than 6% on solvency, 0% on liquidity, 10% on profitability and 34% on growth.

The bankruptcy probability was computed on 29-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Six signals.

lowers riskraises riskneutral

Liquidity: current ratio 0.01

NBB · annual accounts

Size: total assets €607,532

Companies of this size fail less often; how much that weighs depends on the rest of its profile.

NBB · annual accounts

Negative equity -€129.9m

NBB · annual accounts

Loss of €12.0m, the second in a row (financial year 2025)

NBB · annual accounts

Negative equity

The 2025 annual accounts show negative equity and a net loss.

NBB · annual accounts 2025

Equity per financial year

18192021232425

2018 to 2025 · latest year -€129.9m

Latest accounts filed on time

The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 08-06-2026, 53 days ahead of the deadline.

NBB · 8 filings

Deviation from the deadline

2025

53 days early

2024

44 days early

2023

9 days early

2022

73 days late

2021

6 days early

2020

51 days early

2019

35 days early

← before the deadline after the deadline →

tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 18 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)

Next filing not due yet

The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 23 July (4 of the last 5 filed years within 45 days of that day).

Companies Code · seven months

Where today falls in the filing period

30-10-2026 today31-12-2026 year end31-07-2027 deadline

No strike-offs in the KBO publications

Searched since 2021.

KBO publications · our coverage

08-06-2026 Annual accounts filedfinancial year 2025 · full…
07-05-2026 Resignation: Rolfe van de Spreng (director)Appointment: Erica Silbiger (director)
06-01-2026 Resignation: Jean-Antoine de Los Frailes (director)Appointment: Rolfe van de Spreng…

Key points

Risk: Negative equityfinancial year 2025: debts exceed assets -€129.9m View
Risk: 7 loss-making years in a rowloss financial year 2025 -€12.0m View
Caution: Among the weakest 5% on solvencysector median 49.2% · 239 companies -21385.2% View
Positive: Result rose in 2025from -€60.6m to -€12.0m ▲ 80.3% View
Caution: Board changedlatest change 07-05-2026 · 1 in office 1 joined · 2 left View
Controlled by AbbVie Inc. parent View

By topic

Financials

Financial year: 2025
Total assets: €607,532
Loss: -€12.0m
Solvency: -21385.2%

Total assets▼ 62.8%

Net result

20182025

Go to Financials

Board & ownership

Board: 1 member
Parent: AbbVie Inc.
Auditor: EY Réviseurs d'Entreprises SRL

Erica SilbigerDirector

Go to Board & ownership

Timeline

Events: 15
Since: 2019
Next accounts: by 31-07-2027

17-06-2025Annual accounts filed
31-12-2024Weakest financial year
23-12-2024Resignation: Scott Reents (director)

Go to Timeline

Company details

Sites: 1

Legal form: Public limited company
Activity: Research and development on biotechnologyNACE 72101
Founded: 19-12-2017
Year ends: 31-12
Peppol: Reachable for e-invoices

Go to Company details

Articles of association

Provisions read: 2

Who signs: Each director alone

Go to Articles of association

Key facts about SYNDESI THERAPEUTICS

What is the company number of SYNDESI THERAPEUTICS?: 0686.599.355. In Belgium the VAT number is the company number with BE in front: BE 0686.599.355.
Where is SYNDESI THERAPEUTICS based?: The registered office is at Avenue Einstein 14, 1300 Wavre.Company details
What does SYNDESI THERAPEUTICS do?: According to the KBO register, the main activity is research and development on biotechnology (NACE 72101).
What is the legal form of SYNDESI THERAPEUTICS?: Public limited company (NV).
When was SYNDESI THERAPEUTICS founded?: On 19-12-2017.
Is SYNDESI THERAPEUTICS still active?: Yes, SYNDESI THERAPEUTICS is an active enterprise in the KBO register.
How many employees does SYNDESI THERAPEUTICS have?: On average 1 full-time equivalents in financial year 2021, according to the filed annual accounts.Financials
What is the turnover of SYNDESI THERAPEUTICS?: Not stated in the processed annual accounts. The abridged format for small companies does not require turnover.
Is SYNDESI THERAPEUTICS profitable?: In financial year 2025, SYNDESI THERAPEUTICS made a loss of €12.0m.
Where can I find the annual accounts of SYNDESI THERAPEUTICS?: SYNDESI THERAPEUTICS filed 8 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
When are the next annual accounts of SYNDESI THERAPEUTICS due?: By 31-07-2027, for financial year 2026.Timeline